Overview

DPP-4 Inhibition and TZD for DM Prevention

Status:
Terminated

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.

Phase:

N/A

Details

Lead Sponsor:

Emory University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pioglitazone
Sitagliptin Phosphate